The China National Intellectual Property Administration issued Patent No. ZL 2017 1 1177638.2 for Certified Nutraceuticals’ Type I, Type II, Type V hydrolyzed jellyfish collagen: KollaJell.
The China National Intellectual Property Administration issued Patent No. ZL 2017 1 1177638.2 for Certified Nutraceuticals’ (Pauma Valley, CA) Type I, Type II, Type V hydrolyzed jellyfish collagen: KollaJell. The ingredient is rich in amino acids, calcium-binding proteins, antioxidants, and macronutrients to support a healthy brain and cognitive function.
“KollaJell is a ‘super food’ for the brain,” said Abdul Alkayali, Certified Nutraceuticals senior vice president, sales and marketing, in a press release. “It is an abundant source of amino acids that enable neurons to communicate with each other. In addition, collagen is a major component of the extracellular matrix, which provides structure for the brain and regulates several fundamental neural processes.”
KollaJell is sourced from edible wild-caught cannonball jellyfish and barrel jellyfish. It is protected by U.S. Patent Number 10,287,339 B2.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.